Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Lung Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 100 articles:
HTML format



Single Articles


    September 2020
  1. WOLF J, Seto T, Han JY, Reguart N, et al
    Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
    N Engl J Med. 2020;383:944-957.
    PubMed     Abstract available


    August 2020
  2. DRILON A, Oxnard GR, Tan DSW, Loong HHF, et al
    Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2020;383:813-824.
    PubMed     Abstract available


  3. KURZROCK R
    Selpercatinib Aimed at RET-Altered Cancers.
    N Engl J Med. 2020;383:868-869.
    PubMed    


  4. HOWLADER N, Forjaz G, Mooradian MJ, Meza R, et al
    The Effect of Advances in Lung-Cancer Treatment on Population Mortality.
    N Engl J Med. 2020;383:640-649.
    PubMed     Abstract available


    May 2020
  5. PAIK PK, Felip E, Veillon R, Sakai H, et al
    Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
    N Engl J Med. 2020 May 29. doi: 10.1056/NEJMoa2004407.
    PubMed     Abstract available


  6. DE KONING HJ, van der Aalst CM, Oudkerk M
    Lung-Cancer Screening and the NELSON Trial. Reply.
    N Engl J Med. 2020;382:2165-2166.
    PubMed    


  7. AUTIER P
    Lung-Cancer Screening and the NELSON Trial.
    N Engl J Med. 2020;382:2165.
    PubMed    


  8. KENNEDY MP
    Lung-Cancer Screening and the NELSON Trial.
    N Engl J Med. 2020;382:2164-2165.
    PubMed    


  9. LINDHOLT JS, Sogaard R
    Lung-Cancer Screening and the NELSON Trial.
    N Engl J Med. 2020;382:2164.
    PubMed    


  10. ARMSTRONG KA, Cohen JV, Shepard JO, Folch EE, et al
    Case 16-2020: A 47-Year-Old Woman with Recurrent Melanoma and Pulmonary Nodules.
    N Engl J Med. 2020;382:2034-2043.
    PubMed    


  11. NORONHA V
    The Day My Gut Feeling Led Me Astray.
    N Engl J Med. 2020;382:1880-1881.
    PubMed    


  12. RAMALINGAM SS, Soria JC
    Osimertinib in EGFR-Mutated Advanced NSCLC. Reply.
    N Engl J Med. 2020;382:1864-1865.
    PubMed    


  13. REVANNASIDDAIAH S, Devadas SK, Maka VV
    Osimertinib in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2020;382:1864.
    PubMed    


  14. STAEGE MS
    Osimertinib in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2020;382:1863-1864.
    PubMed    


  15. YAN K
    Osimertinib in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2020;382:1863.
    PubMed    


    March 2020
  16. REYNOLDS KL, Sullivan RJ, Fintelmann FJ, Mansour MK, et al
    Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia.
    N Engl J Med. 2020;382:1150-1159.
    PubMed    


  17. BELLO F, Fagni F
    Nasal Deformity in Granulomatosis with Polyangiitis.
    N Engl J Med. 2020;382:951.
    PubMed    


    February 2020
  18. HELLMANN MD, Ramalingam SS
    Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2020;382:875.
    PubMed    


  19. BERSANELLI M, Tiseo M, Banna GL
    Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2020;382:874-875.
    PubMed    


  20. KIM J, Shin SW
    Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2020;382:874.
    PubMed    


  21. D'SILVA K, Cockrill B, Anderson WJ, Miller AL, et al
    A Rapid Change in Pressure.
    N Engl J Med. 2020;382:563-570.
    PubMed    


    January 2020
  22. DE KONING HJ, van der Aalst CM, de Jong PA, Scholten ET, et al
    Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.
    N Engl J Med. 2020 Jan 29. doi: 10.1056/NEJMoa1911793.
    PubMed     Abstract available


  23. DUFFY SW, Field JK
    Mortality Reduction with Low-Dose CT Screening for Lung Cancer.
    N Engl J Med. 2020 Jan 29. doi: 10.1056/NEJMe1916361.
    PubMed    


  24. RAMALINGAM SS, Vansteenkiste J, Planchard D, Cho BC, et al
    Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2020;382:41-50.
    PubMed     Abstract available


    December 2019
  25. THOMAS C, Vleugels RA, Kwiatkowski DJ, Levy B, et al
    Facing Uncertainty.
    N Engl J Med. 2019;381:2253-2259.
    PubMed    


    November 2019
  26. THOMAS C, Vaidya A, Kwiatkowski DJ, Rao DA, et al
    Facing Uncertainty.
    N Engl J Med. 2019;381:e39.
    PubMed    


  27. MIYASHIRO D, Sanches JA
    Velvety Palms.
    N Engl J Med. 2019;381:e35.
    PubMed    


  28. MACKAY DF, Russell ER, Stewart K, MacLean JA, et al
    Neurodegenerative Disease Mortality among Former Professional Soccer Players.
    N Engl J Med. 2019;381:1801-1808.
    PubMed     Abstract available


    September 2019
  29. HELLMANN MD, Paz-Ares L, Bernabe Caro R, Zurawski B, et al
    Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1910231.
    PubMed     Abstract available


  30. GUINEY TE, Lopes MS, Kalra MK, Mooradian MJ, et al
    Case 30-2019: A 65-Year-Old Woman with Lung Cancer and Chest Pain.
    N Engl J Med. 2019;381:1268-1277.
    PubMed    


  31. GARRIDO-ABAD P, Garcia-Martin L
    Vocal Cord Metastasis.
    N Engl J Med. 2019;381:e18.
    PubMed    


    June 2019
  32. SALEM JE, Allenbach Y, Vozy A, Brechot N, et al
    Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
    N Engl J Med. 2019;380:2377-2379.
    PubMed    


    May 2019
  33. YU D, Blair JEA
    A STEMI Mimic.
    N Engl J Med. 2019;380:e41.
    PubMed    


    March 2019
  34. ANTONIA SJ
    Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2019;380:990.
    PubMed    


  35. KIM YH
    Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2019;380:989-990.
    PubMed    


    February 2019
  36. HORN L, Liu SV
    Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2019;380:889-890.
    PubMed    


  37. DIKER O
    Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer.
    N Engl J Med. 2019;380:889.
    PubMed    


  38. WEISS GJ, Addeo A
    Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer.
    N Engl J Med. 2019;380:888-889.
    PubMed    


    December 2018
  39. AMPOLLINI L, Rusca M
    Erythroderma and a Pulmonary Nodule.
    N Engl J Med. 2018;379:e41.
    PubMed    


  40. ANTONIA SJ, Villegas A, Daniel D, Vicente D, et al
    Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
    N Engl J Med. 2018;379:2342-2350.
    PubMed     Abstract available


    November 2018
  41. PATIL T, Pacheco JM
    Miliary Metastases in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;379:1945.
    PubMed    


  42. MANLEY C, Olszanski A
    Melanoma in the Bronchus.
    N Engl J Med. 2018;379:e36.
    PubMed    


    October 2018
  43. NEILAN TG, Price MC, Sanborn DY, Gainor JF, et al
    Case 33-2018: A 57-Year-Old Man with Confusion, Fever, Malaise, and Weight Loss.
    N Engl J Med. 2018;379:1658-1669.
    PubMed    


  44. KWATRA SG, Stander S, Kang H
    PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist.
    N Engl J Med. 2018;379:1578-1579.
    PubMed    


    September 2018
  45. CAMIDGE DR, Kim HR, Ahn MJ, Yang JC, et al
    Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMoa1810171.
    PubMed     Abstract available


  46. HORN L, Mansfield AS, Szczesna A, Havel L, et al
    First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
    N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMoa1809064.
    PubMed     Abstract available


  47. PAZ-ARES L, Luft A, Vicente D, Tafreshi A, et al
    Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMoa1810865.
    PubMed     Abstract available


  48. ASHRAF N
    Atezolizumab Treatment of Nonsquamous NSCLC.
    N Engl J Med. 2018;379:1187-8.
    PubMed    


  49. MOUNTZIOS G, Calles A, Addeo A
    Atezolizumab Treatment of Nonsquamous NSCLC.
    N Engl J Med. 2018;379:1187.
    PubMed    


  50. RECK M, Jotte RM, Socinski MA
    Atezolizumab Treatment of Nonsquamous NSCLC.
    N Engl J Med. 2018;379:1188.
    PubMed    


  51. DIKER O
    Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e18.
    PubMed    


  52. SUN R, Rich MW, Wei LJ
    Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e18.
    PubMed    


  53. GIL-SIERRA MD, Fenix-Caballero S, Alegre-del Rey E
    Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e19.
    PubMed    


  54. VANDERLAAN PA, Rangachari D, Costa DB
    Lung Cancer with a High Tumor Mutational Burden.
    N Engl J Med. 2018;379:1093.
    PubMed    



  55. Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e18.
    PubMed    



  56. Lung Cancer with a High Tumor Mutational Burden.
    N Engl J Med. 2018;379:1093-1094.
    PubMed    


  57. CONTI L, Gatt S
    Squamous-Cell Carcinoma of the Lung.
    N Engl J Med. 2018;379:e17.
    PubMed    


  58. AL-KINDI S, Al-Juhaishi T, Yaqoob Z
    Incidence of Lung Cancer among Young Women.
    N Engl J Med. 2018;379:988-9.
    PubMed    


  59. BERLIN I
    Incidence of Lung Cancer among Young Women.
    N Engl J Med. 2018;379:988.
    PubMed    


  60. FUNATOGAWA I
    Incidence of Lung Cancer among Young Women.
    N Engl J Med. 2018;379:988.
    PubMed    



  61. Incidence of Lung Cancer among Young Women.
    N Engl J Med. 2018;379:988-991.
    PubMed    


    August 2018

  62. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    N Engl J Med. 2018;379:e14.
    PubMed    


  63. LOMMATZSCH M, Bratke K, Stoll P
    Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    N Engl J Med. 2018;379:e14.
    PubMed    


  64. YANG X, Yin R, Xu L
    Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    N Engl J Med. 2018;379:e14.
    PubMed    


    June 2018
  65. SOCINSKI MA, Jotte RM, Cappuzzo F, Orlandi F, et al
    Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
    N Engl J Med. 2018;378:2288-2301.
    PubMed     Abstract available


  66. DE KOCK L, Fahiminiya S, Fiset PO, Astigarraga I, et al
    Infantile Pulmonary Teratoid Tumor.
    N Engl J Med. 2018;378:2238-2240.
    PubMed    


  67. SCLAFANI A, VanderLaan P
    Lymphangioleiomyomatosis.
    N Engl J Med. 2018;378:2224.
    PubMed    


    May 2018
  68. SCHILLER JH
    A New Standard of Care for Advanced Lung Cancer.
    N Engl J Med. 2018;378:2135-2137.
    PubMed    


  69. JEMAL A, Miller KD, Ma J, Siegel RL, et al
    Higher Lung Cancer Incidence in Young Women Than Young Men in the United States.
    N Engl J Med. 2018;378:1999-2009.
    PubMed     Abstract available


  70. ELMORE SNC
    p53 and Me.
    N Engl J Med. 2018;378:1962-1963.
    PubMed    


    April 2018
  71. GANDHI L, Rodriguez-Abreu D, Gadgeel S, Esteban E, et al
    Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1801005.
    PubMed     Abstract available


  72. FORDE PM, Chaft JE, Smith KN, Anagnostou V, et al
    Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1716078.
    PubMed     Abstract available


  73. HELLMANN MD, Ciuleanu TE, Pluzanski A, Lee JS, et al
    Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
    N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1801946.
    PubMed     Abstract available


  74. MAMDANI H, Grethlein SJ
    Pulmonary Metastases from Chondroblastic Osteosarcoma.
    N Engl J Med. 2018;378:1429.
    PubMed    


    March 2018
  75. CHOI JY, Choi YJ, Shin SW
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1262.
    PubMed    


  76. ROCA E, Amoroso V, Berruti A
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261-2.
    PubMed    


  77. WARD MC, Prabhu RS, Burri SH
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261.
    PubMed    



  78. Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261-1263.
    PubMed    


  79. WEINSTOCK M, Vaidya A, El-Chemaly S, Godleski J, et al
    The Verge of Collapse.
    N Engl J Med. 2018;378:e18.
    PubMed    



  80. Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:868-870.
    PubMed    


  81. SANTONI M, Battelli N, Buti S
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:869.
    PubMed    


  82. COPUR MD, Gauchan D, Ramaekers R
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:868.
    PubMed    


    January 2018
  83. POPAT S
    Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:192-193.
    PubMed    


    November 2017
  84. SORIA JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, et al
    Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Nov 18. doi: 10.1056/NEJMoa1713137.
    PubMed     Abstract available


  85. SOHAL SS, Walers EH
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1998-9.
    PubMed    


  86. REN C, Han C, Wang D
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1998.
    PubMed    


  87. KWON HW, Ham SY, Shin SW
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1997-8.
    PubMed    


  88. RIZVI NA, Peters S
    Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1986-1988.
    PubMed    



  89. Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1999.
    PubMed    


    September 2017
  90. ANTONIA SJ, Villegas A, Daniel D, Vicente D, et al
    Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Sep 8. doi: 10.1056/NEJMoa1709937.
    PubMed     Abstract available


    August 2017
  91. RECK M, Rabe KF
    Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:849-861.
    PubMed    


    June 2017
  92. CARBONE DP, Reck M, Paz-Ares L, Creelan B, et al
    First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;376:2415-2426.
    PubMed     Abstract available


  93. PETERS S, Camidge DR, Shaw AT, Gadgeel S, et al
    Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Jun 6. doi: 10.1056/NEJMoa1704795.
    PubMed     Abstract available


  94. ROBLES AI, Zenklusen JC
    Seeing the Forest through the Phylogenetic Tree.
    N Engl J Med. 2017;376:2190-2191.
    PubMed    


    May 2017
  95. NISHINO M, Hatabu H
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1992-3.
    PubMed    


  96. YIN Y, Li J
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993.
    PubMed    



  97. Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993-4.
    PubMed    


  98. ZHANG BM, Aleshin A, Lin CY, Ford J, et al
    IDH2 Mutation in a Patient with Metastatic Colon Cancer.
    N Engl J Med. 2017;376:1991-2.
    PubMed    


    April 2017
  99. JAMAL-HANJANI M, Wilson GA, McGranahan N, Birkbak NJ, et al
    Tracking the Evolution of Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Apr 26. doi: 10.1056/NEJMoa1616288.
    PubMed     Abstract available


    March 2017
  100. DEFILIPPIS EM, Vaidya A, Ramani S, French C, et al
    Under Pressure.
    N Engl J Med. 2017;376:e23.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: